Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNK-CAT: Tenecteplase vs Alteplase Before Thrombectomy in Stroke
NCT05626972Phase 3Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoints: Modified Rankin Scale Score at 3 months, Mortality Rate at 3 months and 1 more. Status: unknown.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05626972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626972.